Drugmakers try evasion, tougher negotiations to fight new U.S. insurer tactic

NEW YORK (Reuters) - In the escalating battle over U.S. prescription drug prices, major pharmaceutical companies are scrambling to limit the economic damage from a new U.S. insurer tactic that coaxes patients away from expensive drugs.